Latest Period
Q4 2025
Security Snapshot
FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) Institutional Ownership
CUSIP: 31447P100
13F Institutional Holders and Ownership History from Q3 2017 to Q1 2026
Institutions Reporting
95
Shares (Excl. Options)
15,538,482
Price
$7.70
Save this security page for your next review
Keep this CUSIP in your watchlists so you can revisit quarter changes from one place. If you create an account from here, we will bring you back after verification.
- Type / Class
- Equity / Common Shares, no par value
- Symbol
- FENC on Nasdaq
- Shares outstanding
- 34,763,175
- Price per share
- $6.40
- All holders as of 31 Dec 2025
- Q4 2025
- Total 13F shares
- 15,538,482
- Total reported value
- $119,646,345
- % of total 13F portfolios
- 0%
- Share change
- +1,579,597
- Value change
- +$11,219,093
- Number of holders
- 95
- Price from insider filings
- $6.40
Reported Shares, Excluding Options vs Price
Reported Value, Excluding Options
Total Investors
Quick Takeaways
- FENC - FENNEC PHARMACEUTICALS INC. - Common Shares, no par value is tracked under CUSIP 31447P100.
- 95 institutions reported positions in Q4 2025.
- 6 significant owners is listed from Schedule 13D/13G reporting.
What Changed
- Holder count moved from 95 to 30 between Q4 2025 and Q1 2026.
- Reported value moved from $119,646,345 to $21,144,566.
Why This Matters
- You can quickly see who holds this security, then open quarter and manager detail pages for full evidence.
- 13F and Schedule 13D/13G sections are kept together so you can cross-check institutional and beneficial ownership context.
Source Evidence
Source: SEC Form 13F
Open SEC Evidence
Latest holder context comes from 95 institutions filings for Q4 2025.
Investment Quick Answers
What is CUSIP 31447P100?
CUSIP 31447P100 identifies FENC - FENNEC PHARMACEUTICALS INC. - Common Shares, no par value in SEC 13F datasets.
Where can I see the latest institutional holders?
Review the Q4 2025 holders report and the ownership history table below.
Next ownership checks
Use the next link that matches the question you still need to answer about this security.
- Latest 13F filings when you want to inspect fresh institutional portfolio moves.
- Latest Schedule 13D/13G reports when you need large-owner changes outside the 13F cycle.
- All institutional ownership pages to compare this security with other holder-history pages.
Recent Quarterly Holder Reports
Open recent reporting periods for CUSIP 31447P100:
Significant Owners of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) based on Schedule 13D/G filings
| Filer | Ownership | Change % | Holdings Value | Net Change | Nb Shares | Change % | Reporting Name | Report Period |
|---|---|---|---|---|---|---|---|---|
| Sonic Fund II, L.P. | 8.2% | $21,503,685 | 2,799,959 | Kam Lawrence | 31 Dec 2025 | |||
| Rosalind Advisors, Inc. | 9.8% | +29% | $21,095,731 | +$5,145,600 | 2,746,840 | +32% | Rosalind Advisors, Inc. | 31 Dec 2025 |
| Southpoint Capital Advisors LP | 8% | $21,135,329 | 2,744,741 | Southpoint Master Fund, LP | 31 Dec 2025 | |||
| Solas Capital Management, LLC | 8.2% | +17% | $12,807,729 | +$1,862,809 | 2,250,919 | +17% | Solas Capital Management, LLC | 31 Dec 2024 |
| HIRSCHMAN ORIN | 5.7% | $12,186,826 | 1,981,501 | Orin Hirschman | 31 Mar 2026 | |||
| DG Capital Management, LLC | 4.1% | $6,342,597 | 1,114,692 | DG Capital Management, LLC | 31 Dec 2024 |
As of 31 Dec 2025, 95 institutional investors reported holding 15,538,482 shares of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC). This represents 45% of the company’s total 34,763,175 outstanding shares.
Top 25 Institutional Shareholders
The largest institutional shareholders of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) together control 43% of the company’s outstanding shares — a level of ownership often associated with strong institutional conviction and long‑term capital commitment.
| Institution | Ownership % | Shares Held | Share Change % | Portfolio % | Holdings Value |
|---|---|---|---|---|---|
| Southpoint Capital Advisors LP | 7.9% | 2,744,741 | -33% | 0.49% | $21,134,506 |
| Rosalind Advisors, Inc. | 7.5% | 2,613,508 | +26% | 7.7% | $20,124,012 |
| Solas Capital Management, LLC | 7.4% | 2,560,726 | +17% | 11% | $19,717,590 |
| AIGH Capital Management LLC | 4.5% | 1,581,501 | +132% | 3.6% | $12,177,558 |
| BlackRock, Inc. | 3.6% | 1,234,277 | +1.9% | 0% | $9,503,934 |
| VANGUARD GROUP INC | 3.1% | 1,067,651 | +12% | 0% | $8,220,912 |
| AWM Investment Company, Inc. | 2% | 711,869 | 0.53% | $5,481,391 | |
| STATE STREET CORP | 1% | 352,775 | +3.4% | 0% | $2,716,368 |
| GEODE CAPITAL MANAGEMENT, LLC | 0.85% | 297,100 | -1.2% | 0% | $2,287,669 |
| MORGAN STANLEY | 0.7% | 242,476 | +4.3% | 0% | $1,867,066 |
| Apis Capital Advisors, LLC | 0.59% | 204,000 | 0.27% | $1,570,800 | |
| CITADEL ADVISORS LLC | 0.57% | 199,749 | +86% | 0% | $1,538,067 |
| GENDELL JEFFREY L | 0.4% | 139,559 | 0% | 0.02% | $1,074,605 |
| MARSHALL WACE, LLP | 0.37% | 127,693 | 0% | $983,236 | |
| Lion Point Capital, LP | 0.32% | 112,434 | -8.6% | 4.5% | $865,742 |
| NORTHERN TRUST CORP | 0.32% | 112,092 | -14% | 0% | $863,108 |
| Potomac Capital Management, Inc. | 0.27% | 95,100 | 0% | 0.61% | $732,270 |
| BRIDGEWAY CAPITAL MANAGEMENT, LLC | 0.24% | 83,005 | +170% | 0.01% | $639,139 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 0.16% | 57,249 | 0% | 0% | $440,817 |
| Trexquant Investment LP | 0.15% | 51,380 | 0% | $395,626 | |
| STATE OF WISCONSIN INVESTMENT BOARD | 0.15% | 51,000 | +59% | 0% | $392,700 |
| Hartford Financial Management Inc. | 0.15% | 50,646 | 0% | 0.1% | $389,975 |
| Stonepine Capital Management, LLC | 0.14% | 50,000 | 0.31% | $385,000 | |
| Bank of New York Mellon Corp | 0.14% | 49,219 | -5.9% | 0% | $378,989 |
| Qube Research & Technologies Ltd | 0.13% | 44,692 | 0% | $344,128 |
Institutional Holders of FENNEC PHARMACEUTICALS INC. - Common Shares, no par value (FENC) across Reporting Periods
| Period | Reported Shares, Excl. Options | Value, Excl. Options | Value Change | Price (Median) | Investors |
|---|---|---|---|---|---|
| 2026 Q1 | 3,438,360 | $21,144,566 | +$2,798,186 | $6.15 | 30 |
| 2025 Q4 | 15,538,482 | $119,646,345 | +$11,219,093 | $7.70 | 95 |
| 2025 Q3 | 13,863,242 | $129,757,954 | +$2,614,052 | $9.36 | 83 |
| 2025 Q2 | 13,599,927 | $112,877,891 | +$2,365,581 | $8.30 | 77 |
| 2025 Q1 | 13,390,166 | $81,552,976 | -$1,522,792 | $6.09 | 68 |
| 2024 Q4 | 16,048,764 | $101,424,546 | +$7,283,101 | $6.32 | 64 |
| 2024 Q3 | 14,931,283 | $74,650,166 | +$2,539,947 | $5.00 | 62 |
| 2024 Q2 | 14,360,522 | $87,742,748 | -$6,402,237 | $6.11 | 62 |
| 2024 Q1 | 14,487,904 | $161,105,911 | -$6,099,282 | $11.12 | 64 |
| 2023 Q4 | 15,010,968 | $168,423,713 | +$8,238,895 | $11.22 | 55 |
| 2023 Q3 | 14,291,968 | $107,334,991 | +$1,444,870 | $7.51 | 54 |
| 2023 Q2 | 14,066,767 | $124,212,045 | +$9,438,707 | $8.83 | 54 |
| 2023 Q1 | 13,040,023 | $108,481,973 | +$4,197,539 | $8.32 | 53 |
| 2022 Q4 | 12,451,231 | $119,532,387 | -$8,641,346 | $9.60 | 42 |
| 2022 Q3 | 11,367,575 | $92,077,143 | +$913,826 | $8.10 | 29 |
| 2022 Q2 | 11,273,521 | $63,103,949 | -$835,989 | $5.63 | 24 |
| 2022 Q1 | 11,437,604 | $64,049,354 | +$542,291 | $5.60 | 24 |
| 2021 Q4 | 11,346,536 | $49,924,524 | -$2,427,096 | $4.40 | 26 |
| 2021 Q3 | 11,649,016 | $109,719,412 | -$3,040,624 | $9.42 | 30 |
| 2021 Q2 | 12,077,739 | $88,042,799 | -$14,218,632 | $7.29 | 36 |
| 2021 Q1 | 14,373,653 | $89,259,363 | -$593,443 | $6.21 | 49 |
| 2020 Q4 | 14,462,317 | $107,736,409 | +$5,043,456 | $7.45 | 48 |
| 2020 Q3 | 13,830,913 | $83,811,378 | -$1,125,208 | $6.06 | 51 |
| 2020 Q2 | 13,870,610 | $115,816,682 | +$37,949,605 | $8.35 | 53 |
| 2020 Q1 | 9,462,229 | $56,207,308 | +$983,452 | $5.94 | 25 |
| 2019 Q4 | 9,292,337 | $60,284,409 | -$38,066 | $6.48 | 26 |
| 2019 Q3 | 8,465,309 | $40,716,816 | -$1,958,704 | $4.81 | 21 |
| 2019 Q2 | 8,988,085 | $35,952,664 | -$3,100,726 | $4.00 | 25 |
| 2019 Q1 | 9,638,104 | $46,743,906 | -$525,691 | $4.85 | 44 |
| 2018 Q4 | 9,742,725 | $62,159,250 | +$1,863,710 | $6.38 | 45 |
| 2018 Q3 | 9,435,050 | $77,373,042 | -$276,921 | $8.20 | 45 |
| 2018 Q2 | 9,392,799 | $98,080,873 | +$18,177,598 | $10.44 | 43 |
| 2018 Q1 | 7,623,491 | $92,186,011 | +$4,858,661 | $12.09 | 21 |
| 2017 Q4 | 6,949,133 | $69,588,032 | +$18,006,732 | $10.00 | 16 |
| 2017 Q3 | 5,214,611 | $57,723,043 | +$57,723,043 | $11.03 | 10 |